Article

Pseudobulbar Affect: Considerations for Managed Care Professionals

https://www.pharmacytimes.org/landing/1073

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!
Related Videos
Dr Elise Tremblay
Angel Qin, MD
Surbhi Sidana, MD, MBBS, Stanford University
Related Content
BRUIN CLL-314 was the first-ever head-to-head trial of pirtobrutinib versus ibrutinib that included treatment-naive patients. | Image credit: fotogurmespb - stock.adobe.com
August 8th 2025

New Pirtobrutinib Data Compare Favorably With Ibrutinib in CLL/SLL

Jared Kaltwasser
AJMC podcast banner
August 8th 2025

What It Takes to Improve Guideline-Based Heart Failure Care With Ty J. Gluckman, MD

Hayden E. Klein Skylar Jeremias Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC
Doctor examining MRI images of multiple sclerosis MS | Image credit: New Africa - stock.adobe.com
August 8th 2025

Advances in MS Therapies Reshape the Treatment Landscape

Skylar Jeremias
The Center for Biosimilars podcast banner
August 8th 2025

Follow the Science: Bridging the Biosimilar Gap With Dr Hillel Cohen

Skylar Jeremias Hillel P. Cohen, PhD Giuseppe Randazzo
Processed foods | Image credit: colorcocktail - stock.adobe.com
August 8th 2025

Children’s Diets Primarily Made Up of Ultra-Processed Foods, Finds CDC

Julia Bonavitacola
Urticaria. | Image Credit: StockWorld - stock.adobe.com
August 8th 2025

Chronic Spontaneous Urticaria Linked to Higher Patient Burden, Worse Quality of Life

Cameron Santoro

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo